Danish Biotech Hoba Therapeutics Raises $23M in Series A Funding to Develop Groundbreaking Treatments for Chronic Pain and Hearing Loss

Hoba Therapeutics, an innovative Danish biotech company, has successfully raised an impressive $23 million in funding to advance its groundbreaking work in restorative treatments for chronic pain disorders and sensorineural hearing loss. Founded in 2016 with the backing of Novo Holdings and Borean Innovation, Hoba is on a mission to address the significant unmet medical needs faced by millions of patients worldwide. The funds will primarily be allocated toward the development of its lead candidates, HB-086 and HB-097. HB-086 is a non-opioid compound designed to tackle chronic neuropathic pain by specifically targeting the peripheral nervous system, offering a novel mechanism of action aimed at reversing both the pain experience and its underlying causes. Concurrently, HB-097 demonstrates promising preclinical data as a pharmacological treatment for sensorineural hearing loss, exhibiting both preventive and regenerative effects that protect nerve cells and repair existing damage. Given that chronic neuropathic pain affects approximately 6–8% of the European population and significantly burdens healthcare systems globally, Hoba Therapeutics’ focus on safe, effective, and innovative treatment options is timely and crucial. The rising prevalence of such disorders speaks to the critical need for new therapies, with the global neuropathic pain market projected to exceed $7.6 billion. With the recent funding, Hoba Therapeutics is poised to make meaningful strides in addressing these pressing health challenges, ultimately improving the quality of life for countless individuals suffering from chronic pain and hearing loss.